Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
LL-37 vs VIP (Vasoactive Intestinal Peptide)
An educational, source-based comparison of LL-37 and VIP (Vasoactive Intestinal Peptide) — how each peptide works, what it's researched for, and what to know before going deeper.
Human cathelicidin peptide with antimicrobial and immune-modulating activity.
The only human cathelicidin antimicrobial peptide. Research demonstrates broad antimicrobial activity against bacteria, viruses, and fungi, plus immunomodulatory effects on neutrophils, macrophages, and wound healing.
- Chronic biofilm infections
- Wound healing and dermatology
- Innate immune modulation
- • Not FDA-approved.
- • Pro-inflammatory effects possible at higher doses.
Neuropeptide researched for immune modulation and lung protection.
A 28-amino-acid neuropeptide with broad immunomodulatory, anti-inflammatory, and bronchodilatory effects. Acts via VPAC1 and VPAC2 receptors to regulate T-cell function, macrophage polarization, and airway smooth muscle tone.
- Acute respiratory distress syndrome (ARDS)
- Chronic inflammatory conditions
- Autoimmune modulation
- Bronchial asthma and COPD
- • Short half-life limits therapeutic utility; analogs in development.
- • Not FDA-approved in native form.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Two cited studies; independent replication needed.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| LL-37 | LL-37: a multifunctional host-defense peptide | Frontiers in Immunology | 2020 | Comprehensive review of antimicrobial and immunomodulatory roles. |
| VIP (Vasoactive Intestinal Peptide) | VIP in acute respiratory distress syndrome | Critical Care Medicine | 2021 | Demonstrated lung-protective effects in preclinical ARDS models. |
| VIP (Vasoactive Intestinal Peptide) | VIP and immune tolerance | Frontiers in Immunology | 2019 | Reviewed mechanisms of T-regulatory cell induction and immune homeostasis. |
Side-effect & safety grid
- Not FDA-approved.
- Pro-inflammatory effects possible at higher doses.
- Short half-life limits therapeutic utility; analogs in development.
- Not FDA-approved in native form.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
LL-37 vs VIP (Vasoactive Intestinal Peptide) — Key differences
- Class: LL-37 is classified as Immune · Antimicrobial, while VIP (Vasoactive Intestinal Peptide) is Immune · Respiratory.
- Primary research focus: LL-37 — chronic biofilm infections; VIP (Vasoactive Intestinal Peptide) — acute respiratory distress syndrome (ards).
- Tag: Immune · Antimicrobial vs Immune · Respiratory.